In a study of IFN-β treatment effects in RRMS, we found that treatment with IFN- β reduced the expression of CD134 on CD26HIGH CD4+ T cells [36], in accordance with what we found in natalizumab-treated patients in our study. This evidence concerns the gene CD4 and relapsing-remitting multiple sclerosis.